Gilvetmab

Gilvetmab – For Veterinary Professionals

Merck Animal Health has conditional approval for a new cancer treatment.

What you need to know:

  • Gilvetmab is a caninized monoclonal antibody against canine programmed cell death receptor-1
  • It is indicated for the treatment of dogs with mast cell tumors or melanomas

Want to stay up-to-date on Gilvetmab?

Fill out the form to receive updates and product information as they are released.

“*” indicates required fields

emailconsent
This field is for validation purposes and should be left unchanged.

INDICATIONS: For the treatment of dogs with mast cell tumors or melanomas. This product has demonstrated a reasonable expectation of efficacy and a preliminary safety profile in reducing the solid tumor burden in dogs with stage I, II, and III mast cell tumors or dogs with stage II and III melanomas. This product license is Conditional; safety, efficacy, and potency have not been fully evaluated. For more information regarding safety, see productdata.aphis.usda.gov. This product contains gilvetmab, a caninized monoclonal antibody against canine programmed cell death receptor-1.